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Abstract: Raynaud’s phenomenon is a clinical disorder with episodic digital ischemic 
vasospasm triggered by cold- or emotional-stress. It was first mentioned by Maurice Raynaud 
in 1862 describing “a local asphyxia of the extremities” and was further divided into primary 
Raynaud’s disease and secondary Raynaud’s phenomenon, which is often related to connective 
tissue diseases, but also physical or chemical strain. Though pathophysiology of Raynaud’s 
phenomenon is still poorly understood, systemic and local vascular effects are most likely to 
be involved in primary Raynaud’s disease. In secondary Raynaud’s phenomenon additional 
abnormalities in vascular structure and function may play the major role. Thus, medical treatment 
of Raynaud’s phenomenon remains unsatisfactory, due to limited understanding of pathophysi-
ological mechanisms. This review addresses current evidence for medical treatment of primary 
and secondary Raynaud’s phenomenon with regard to pathophysiological mechanisms as well 
as future perspectives.
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Definition and epidemiology
Raynaud’s phenomenon is described as episodic digital ischemic vasospasm triggered 
by cold- or emotional-stress leading to a pale and cyanotic skin with a postischemic 
phase of hyperemia; the typical “tricolore phenomenon”.1 However, because a clear 
definition and nomenclature of Raynaud’s phenomenon is still lacking, we use the 
terms primary Raynaud’s disease and secondary Raynaud’s phenomenon throughout 
this review.
Raynaud’s disease was first mentioned by Maurice Raynaud in 1862 describing 
“a local asphyxia of the extremities” and was further divided into primary Raynaud’s 
disease and secondary Raynaud’s phenomenon by Thomas Lewis.1,2 Some criteria 
were proposed to diagnose primary rather than secondary Raynaud’s phenomenon. 
These include typical symptoms of digital vasospasm, absence of peripheral vascular 
disease, no evidence of tissue necrosis, normal nailfold capillaries, a negative anti-
nuclear antibody test and a normal sedimentation rate.3 Moreover, primary Raynaud’s 
disease typically affects all fingers, whereas secondary Raynaud’s phenomenon has 
an asymmetric distribution in most cases.
Primary Raynaud’s disease is common, with a prevalence of 3% to 5% in the general 
population, and remains uncomplicated without permanent injury.3 The underlying 
mechanisms of temporary vasospasm are still poorly understood, but are suggested to 
be purely functional. However, secondary Raynaud’s phenomenon occurs in patients 
with connective tissue disease, but is also driven by physical or chemical strain and Vascular Health and Risk Management 2010:6 208
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might have a more severe progression with digital necrosis 
and ulceration leading to disability.4
Pathophysiology
The pathophysiology of Raynaud’s phenomenon remains 
unclear. In contrast to the first description by Maurice 
Raynaud, vascular rather than neural effects were suggested 
to play the major role.1 Hence, systemic and local vascular 
effects were most likely to be involved in primary Raynaud’s 
disease, whereas additional abnormalities in vascular struc-
ture and vascular function are suggested to cause secondary 
Raynaud’s phenomenon.4
Systemic vascular effects
The key issue of Raynaud’s phenomenon is likely to be the 
imbalance of vasoconstriction and vasodilation due to altera-
tions in neural control of vascular tone and circulating media-
tors (Figure 1).5 These mechanisms are suggested to play a 
major role in secondary Raynaud’s phenomenon due to con-
nective tissue disease as systemic sclerosis. In these patients, 
circulating levels of endothelin-1, a potent vasoconstrictor, 
but also involved in fibrosis and structural vascular changes, 
are significantly increased.6 Thus, inhibition of endothelin-
1 receptors might affect vascular remodeling, proliferation 
of smooth-muscle cells as well as fibroblasts as a possible 
treatment target in patients with systemic sclerosis.7
Another key player in vasoconstriction and likely in 
pathogenesis of Raynaud’s phenomenon is angiotensin II. The 
renin-angiotensin system (RAS) plays a major role in regula-
tion of vascular tone, but also in vascular oxidative stress and 
remodeling.8,9 The role of the RAS in Raynaud’s phenomenon 
is yet unknown;4 however, in patients with cutaneous systemic 
sclerosis, circulating levels of angiotensin II are increased 
which might offer a therapeutic approach with angiotensin-
converting enzyme (ACE) inhibitors or angiotensin-receptor 
blockers.10
Vasoconstrictive mediators are counterbalanced by 
vasodilators such as nitric oxide or prostaglandins. Despite 
vasodilating properties, prostaglandins are suggested 
to inhibit platelet aggregation as well as chemotaxis of 
Figure 1 imbalance of vasoconstriction and vasodilation in Raynaud’s disease. Vasodilators as nitric oxide and prostaglandins act via activation of adenylat- or guanylat-cyclase 
modulating protein kinase A/G. Vasoconstriction by endothelin or thromboxane is mediated by g-coupled specific receptors and is suggested to be increased in Raynaud’s 
phenomenon.
Abbreviations: cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanylate monophosphate; DAG, diacylglycerol; GTP, guanylate triphosphate; iP3, inositol triphosphate; 
NO, nitric oxide; PiP2, phosphatidyl inositol biphosphate; PKA, protein kinase A; PKG, protein kinase G; PLC, phospholipase C.Vascular Health and Risk Management 2010:6 209
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leukocytes with consecutive adhesion to the endothelial 
monolayer.11 Moreover, prostaglandins increase fibrino-
lytic activity, which may additionally play an important 
role, especially in patients with secondary Raynaud’s 
phenomenon.12
Consistently, the vasodilator nitric oxide was found to be 
decreased more in secondary than primary Raynaud’s phe-
nomenon, indicating the crucial role of endothelial function 
in vascular regulation and hence in Raynaud’s phenomenon.6 
Hence, endothelial synthesis of nitric oxide plays a major 
role in the pathophysiological mechanisms of Raynaud’s 
phenomenon. Endogenous as well as exogenous nitric oxide 
acts as a potent vasodilator via activation of guanylate-cyclase 
with increased levels of cyclic GMP, therefore resulting in 
dephosphorylation of the myosin light chain of vascular 
smooth muscle cells with consecutive vasodilation.
Local vascular effects
In patients with primary Raynaud’s disease, vascular response 
to alpha2-adrenergic agonists, serotonin and angiotensin II 
was increased during cooling and could be reversed by tyro-
sine kinase inhibitors.13 As a possible mechanism, tyrosine 
phosphorylation was increased during cold exposure in these 
patients. Moreover, the alpha2c-adrenoreceptor is known to 
be important in thermoregulation, with an increased activity 
after cold exposure.14 The underlying pathomechanism is a 
cold-induced increase of reactive oxygen species activating 
the rho/rho-kinase-pathway with consecutive translocation of 
the alpha2c-adrenoreceptor subtype to the cell membrane.15,16 
Thus, increased expression of this receptor might play a role 
in primary Raynaud’s disease, especially in possible effects 
of estrogens on receptor expression, reflecting the high preva-
lence of primary Raynaud’s disease in women.
Moreover, regulation of vascular tone not only depends 
on humoral vasodilating mediators, but also on the release 
of neuropeptides from corresponding nerve endings. The 
calcitonin-gene-related peptide, for example, is a potent 
vasodilator secreted by nerves. In patients with both primary 
and secondary Raynaud’s phenomenon, neuron release was 
demonstrated to be diminished in skin biopsies.17
Treatment
So far, medical treatment of Raynaud’s phenomenon remains 
unsatisfactory. Nevertheless, recent progress in the under-
standing of pathophysiological mechanisms has promoted 
further therapeutic approaches. Some clinical trials have 
revealed promising results, with different substances acting 
as vasodilators or inhibitors of increased vasoconstriction, 
but in general data are limited to small populations enrolled 
in these trials. Moreover, treatment strongly depends on the 
etiology of Raynaud’s phenomenon as well as on individual 
symptoms and presence of digital ulcers.
In both primary and secondary Raynaud’s phenom-
enon, lifestyle modifications are ranked first in the treat-
ment algorithm. Proper body insulation, avoidance of cold 
exposure, stopping possible vasoconstrictive medication 
and smoking cessation play an important role and might be 
a sufficient treatment particularly in patients with primary 
Raynaud’s disease. In patients with secondary Raynaud’s 
phenomenon, avoidance of triggering physical or chemical 
injuries and adequate treatment of the underlying disease 
are fundamental.
With regard to possible pathophysiological mechanisms 
of Raynaud’s disease and phenomenon, medical treatment 
is based on regulation of vasomotion by direct vasodilators 
(nitrates, calcium-channel blockers, prostaglandins, PDE-V 
inhibitors) and inhibition of vasoconstriction (endothelin-
receptor antagonists, angiotensin-receptor blockers, alpha-
receptor blockers). Moreover, substances that increase 
endothelial function such as rho-kinase-inhibitors and statins 
as well as interaction with neural vasoregulation (serotonin-




Nitrates have been used in both primary and secondary Rayn-
aud’s phenomenon with different ways of administration: 
topical with transdermal patches or as different cream or gel 
formulations as well as in oral applications. Sustained release 
patches with glyceroltrinitrate were demonstrated to signifi-
cantly reduce severity (P  0.05) and number (P  0.05) of 
Raynaud attacks in patients with primary (n = 21) and also in 
patients with secondary (n = 21) Raynaud’s phenomenon.18 
However, in 80% of the patients included in these trials, 
headache limited the use of topical nitrates. Moreover, nitrates 
had already been shown to improve digital ulcers compared 
to placebo in the early 1980s.19 Nevertheless, efficacy as 
well as duration of possible beneficial effects of nitrates are 
still not clear in patients with secondary Raynaud’s phenom-
enon, in line with the earliest trials on nitrates in Raynaud’s 
phenomenon of the 1950s.20 Thus, nitrates might be useful 
in primary Raynaud’s disease only and are highly limited by 
their frequent side effects, mainly headache and hypotension, 
irrespective of the way of administration. Interestingly, eight 
clinical trials are currently investigating the effect of topical Vascular Health and Risk Management 2010:6 210
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nitrates on patients with primary and secondary Raynaud’s 
phenomenon. Thus, new data on this class of drug will be 
obtained in the near future.
Calcium channel blockers
In general, less cardioselective calcium channel blockers 
from the dihydropyridine group were suggested to be benefi-
cial in Raynaud’s phenomenon and were first choice treatment 
especially in patients with primary Raynaud’s disease.21 More 
cardioselective calcium channel blockers (phenylalkylamine 
type, benzothiazepine type) were shown to be ineffective in 
patients with severe Raynaud’s phenomenon.22
Calcium channel blockers promote relaxation of vascular 
smooth muscle cells via inhibition of voltage-gated channels, 
leading to peripheral vasodilation. Especially short-acting 
substances such as nifedipine can lead to hypotension with con-
secutive reflex tachycardia, and also headache or flush.23 Use of 
long-acting calcium channel blockers in patients with Raynaud’s 
phenomenon such as felodipine, amlodipine or nitrendipine is 
controversial.24 A meta-analysis of calcium channel blockers in 
patients with primary Raynaud’s disease revealed a significant 
reduction of frequency (–2.8% to 5.0%, P = 0.01) as well as a 
decrease of severity of Raynaud attacks (–33%, P = 0.005).25 
These results are in line with a previous meta-analysis of stud-
ies evaluating the effect of calcium channel blockers in patients 
with Raynaud’s phenomenon due to systemic sclerosis. Within 
2 weeks treatment, there was a reduction of 8.3 attacks per week 
and a 35% decline in severity of clinical symptoms.26 However, 
improvement of clinical symptoms might be a short-term effect 
of treatment with calcium channel blockers as beneficial effects 
can be lost in long-term treatment.24 In a head to head compari-
son of 40 mg nifedipine with intravenous iloprost in patients 
with secondary Raynaud’s phenomenon, there was no effect of 
treatment with nifedipine after 1 year.27
In clinical practice, calcium channel blockers are the 
first choice in primary Raynaud’s disease and have been 
suggested for testing in secondary Raynaud’s phenomenon. 
Treatment should start with low dosages and should be 
titrated with regard to individual symptoms. Recommended 
doses are nifedipine 10 to 30 mg 3 times daily or amlodipine 
5 to 20 mg once daily. In patients with a CREST-syndrome, 
calcium channel blockers can reduce sphincter tone in the 
lower esophagus, in these patients calcium channel blockers 
should be used with caution.
Prostaglandins
Prostaglandins have vasodilatory properties, antiprolifera-
tive effects on vasculature and inhibit platelet aggregation. 
In the treatment of primary and secondary Raynaud’s 
phenomenon, intravenous administration of prostaglandin 
E1 as well as iloprost were shown to be beneficial.28 
In patients with secondary Raynaud’s phenomenon, treat-
ment with iloprost 6 weekly significantly decreased the 
Raynaud’s score compared to the calcium channel blocker 
nifedipin (P = 0.002).27 Moreover, in a multicenter trial 
with 131 patients with systemic sclerosis, iloprost improved 
Raynaud’s score (decrease of 39% vs 22%, P = 0.005) as 
well as healing of digital ulcers in comparison to placebo.29 
However, the role of oral or inhaled preparations of prosta-
glandins is yet not clear and should be evaluated in further 
clinical trials.
Side effects of prostaglandins were dose-dependent and 
a result of peripheral vasodilation with headache, flush and 
nausea. In patients with congestive heart failure, prosta-
glandins may lead to pulmonary edema; hence outpatient 
treatment is not recommended in these patients. Moreover, 
low-dose treatment with prostaglandins (0.5 ng/kg body 
weight per min ilpoprost) is suggested to be equally effec-
tive to high-dose treatment (2.0 ng/kg body weight per min 
ilpoprost) in patients with systemic sclerosis.30
Phosphodiesterase inhibitors
Phosphodiesterase type V (PDE-V) inhibitors mediate vaso-
dilatory effects via accumulation of cyclic guanosine mono-
phosphate in vascular smooth muscle cells and were indicated 
in treatment of erectile dysfunction and more recently in 
pulmonary hypertension.31 In patients with pulmonary 
hypertension due to connective tissue disease, medical 
treatment with PDE-V inhibitors was reported to improve 
symptoms of secondary Raynaud’s phenomenon. Consis-
tently, PDE-V inhibitors were demonstrated to have beneficial 
effects in primary and secondary Raynaud’s phenomenon in 
several studies and case reports. In a single-center trial with 
16 patients with secondary Raynaud’s phenomenon resistant 
to vasodilatory treatment, 4-week treatment with 50 mg 
sildenafil twice daily reduced number of attacks (35 ± 14 vs 
52 ± 18, P = 0.0064) and mean Raynaud’s condition score 
(2.2 ± 0.4 vs 3.0 ± 0.5, P = 0.0386).32 Moreover, capillary 
blood flow improved significantly (P = 0.0004) compared to 
placebo. These data were consistent with two case series in 
which sildenafil reduced frequency and severity of attacks in 
patients with secondary Raynaud’s phenomenon.33,34
In a case-report, tadalafil, another PDE-V inhibitor, 
was reported to be beneficial in a patient with secondary 
Raynaud’s phenomenon not responding to sildenafil.35 
Recent data are in line with this observation. In patients with Vascular Health and Risk Management 2010:6 211
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systemic sclerosis, plasma endothelin-1 levels were reduced 
by daily treatment with tadalafil.36 However, in a randomized, 
cross-over trial comparing tadalafil with placebo in patients 
with Raynaud’s phenomenon and systemic sclerosis, there 
was no significant difference in number, severity and duration 
of Raynaud’s attacks.37
PDE-V inhibitors are one of the most promising class 
of substances for treatment of Raynaud’s phenomenon, but 
more data are needed. A current trial evaluating a novel PDE-
V-inhibitor (SLx-2101) in patients with secondary Raynaud’s 
phenomenon has been completed, and the results are expected 
to be published in early in 2010. At the moment, sildenafil 
shows best evidence for beneficial effects.
Inhibition of vasoconstriction
endothelin receptor antagonists
Endothelin-1 is a potent vasoconstrictor, but is also involved 
in vascular remodeling and local fibrosis, especially in patients 
with secondary Raynaud’s phenomenon.7 In patients with sys-
temic sclerosis, plasma concentrations of endothelin-1 were 
reported to be significantly increased, with enhanced prolifera-
tion and consecutive hypertrophy of vascular smooth muscle 
cells and fibroblasts.38 Thus, inhibition of endothelin-1 exerts 
chronic effects on proliferation and vascular structure rather 
than acute effects on vasomotion. Bosentan is a competitive 
antagonist of both endothelin receptor subtypes A and B, 
with a higher affinity to the first receptor. In the RAPIDS-1 
trial (Randomized Placebo-controlled Investigation of Digital 
Ulcers in Scleroderma) bosentan was evaluated in 122 patients 
with systemic sclerosis. During the treatment period of 
4 months, bostentan reduced onset of new digital ulcers by 
48% in comparison to placebo.39 However, the second endpoint 
of time to healing of digital ulcers did not differ significantly 
between the two treatment arms. The RAPIDS-2 trial included 
188 patients with secondary Raynaud’s phenomenon treated 
with bosentan or placebo for 20 to 32 weeks. Again, number 
of new digital ulcers decreased significantly with bosentan 
(bosentan 1.9 ± 0.2 vs placebo 2.7 ± 0.3, P = 0.035). Based on 
these results, bosentan was marketed in the European Union 
in 2007, being indicated for the reduction of onset of digital 
ulcers in patients with systemic sclerosis. Adverse effects of 
bosentan were particularly increased hepatic aminotransferase 
levels, which were dose-dependent and might occur in about 
10% of patients treated.
Angiotensin receptor blockers
ACE inhibitors as well as ARBs were demonstrated to be 
beneficial in cardiovascular risk patients.40 ACE inhibitors 
and ARBs may also provide improvement in patients with 
Raynaud’s phenomenon, although no definite evidence exists 
to suggest that they are superior to commonly used vasodi-
lating substances.41 Large, randomized, controlled trials are 
needed to compare the effects of ACE inhibitors and ARBs 
with conventional vasodilatory treatment.42 In one small 
trial including patients with primary (n = 25) and secondary 
(n = 27) Raynaud’s phenomenon, losartan was demonstrated 
to decrease frequency of attacks significantly compared to 
nifedipine (P = 0.018) after treatment for 15 weeks. Addi-
tionally, symptoms improved with losartan (P  0.05).43 
Beneficial effects were more pronounced in the subgroup 
of patients with primary Raynaud’s disease. Nevertheless, 
further trials are needed to judge the role of inhibitors of the 
RAS in patients with Raynaud’s phenomenon.
Alpha-adrenoreceptor blockers
Alpha-adrenoreceptors play an important role in sympathetic 
nervous regulation of vascular tone, but also in skin tempera-
ture regulation.41 Prazosin inhibits the alpha-1 postsynaptic 
adrenoreceptor with consecutive peripheral vasodilation. In a 
meta-analysis including 2 trials with a total of 40 patients with 
secondary Raynaud’s phenomenon due to systemic sclero-
sis, prazosin significantly decreased severity and frequency 
of Raynaud’s attacks.44 Despite beneficial effects, several 
side effects as nausea, dizziness, headache, palpitations and 
hypotension limit the use of this substance.
Pathophysiological mechanisms and especially the role 
in thermoregulation of the alpha2c-adrenoreceptor subtype 
have been described above. In a small trial with 13 patients 
with systemic sclerosis and consecutive Raynaud’s phenom-
enon, a specific alpha2c-adrenoreceptor subtype blocker 
decreased time to recovery of skin temperature after cold 
exposure significantly (50% of recovery within 5.8 vs 
10.0 min, P = 0.02).45 Moreover, digital blood flow increased 
compared to placebo. These data were promising, even for 
low frequency of side effects, but further studies with more 
relevant endpoints such as frequency and severity of attacks 
are needed.
Improvement of endothelial 
function
Rho-kinase inhibitors
Rho-kinase is involved in cold-induced modulation of expres-
sion or rather translocation of the alpha2c-adrenoreceptor 
subtype to the plasma membrane. Moreover, rho-kinase 
is a key mediator of pleiotropic effects of statins, with 
beneficial effects on endothelial function and development Vascular Health and Risk Management 2010:6 212
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of atherosclerosis.46 Thus, overactivity of rho-kinase was 
described in several vascular disorders as cerebral ischemia, 
and also coronary vasospasm.47 Fasudil is a potent inhibi-
tor of rho-kinase and was demonstrated to have beneficial 
effects in vasospastic angina.48 Recently, fasudil was shown 
to increase nitric oxide-dependent forearm blood flow and 
to prevent aortic vasoconstriction in an animal model.49,50 
A phase III trial with 24 patients with secondary Raynaud’s 
phenomenon is currently being performed with fasudil at 
the Johns Hopkins University (clinicaltrials.gov identifier: 
NCT00498615). Results may be available in 2010.
Statins
Statins display pleiotropic effects on endothelial function, which 
may be beneficial also in Raynaud’s phenomenon. In patients 
with secondary Raynaud’s phenomenon due to systemic scle-
rosis, 40 mg of atorvastatin (n = 56) or placebo (n = 28) was 
added to ongoing vasodilatory treatment.51 The overall number 
of digital ulcers was significantly reduced in the statin group, 
with a consecutive improvement of quality of life. Another open-
label study is currently investigating the effects of atorvastatin 
on Raynaud’s phenomenon in patients with systemic lupus 
erythematodes. Thus, HMG-CoA-reductase inhibitors were 
suggested to be a promising therapeutic option, especially in 
addition to existing vasodilatory treatment, but more data are 
necessary to judge the definite role of this class of drugs.
Neural vasoregulation
Serotonin reuptake inhibitors
Digital vasomotion may in part depend on serotonin reuptake 
in the central nervous system. Moreover, serotonin reuptake 
may interfere with platelets, but the overall role in Raynaud’s 
phenomenon remains uncertain. In patients with primary 
Raynaud’s disease, 6 weeks’ treatment with the selective sero-
tonin reuptake inhibitor fluoxetine (20 mg) improved severity 
and frequency of attacks compared to nifedipine (40 mg) 
significantly (P  0.001), but effects were less pronounced 
in secondary Raynaud’s phenomenon.52 Consistently, a meta-
analysis of the serotonin-reuptake inhibitor ketanserin 
demonstrated no beneficial effects in secondary Raynaud’s 
phenomenon due to systemic sclerosis.53 Currently there are 
insufficient data to support the routine use of this substance 
in Raynaud’s phenomenon.
Treatment algorithm
Raynaud’s phenomenon is a complex disease with several 
factors suggested to be involved in pathological vasomotion 
and also vascular remodeling. Thus, the decision on 
therapeutic approach has to be taken on a case by case 
basis. In patients with primary Raynaud’s disease, lifestyle 
modifications eclipse medical treatment. Avoidance of cold 
exposure and protection are most important in these patients. 
Moreover, smoking cessation is recommended, despite 
unclear evidence of an association with Raynaud’s phenom-
enon.54 If severity of symptoms requires medical treatment 
despite lifestyle changes, topical nitrates or low-dose treat-
ment with calcium-channel blockers are recommended.
In patients with secondary Raynaud’s phenomenon, treat-
ment of the underlying disease is crucial. In addition to life-
style changes, calcium-channel blockers are also suggested 
to be the first-line treatment in these patients. Patients who 
do not respond or do not tolerate calcium-channel blockers 
may use other vasodilatory substances alone or in combina-
tion, whereas data from clinical trials on combined treatment 
in Raynaud’s phenomenon are not available. A possible 
treatment algorithm suggested by the authors is depicted 
in Figure 2. Further trials of several different substances 
are expected within the next few years. PDE-V inhibitors, 
rho-kinase inhibitors and endothelin-receptor antagonists 
especially seem to be most promising for treatment of both 
primary and secondary Raynaud’s phenomenon.
Patients who develop severe digital ischemia including 
ulcerations often require hospitalization with application of 
intravenous prostaglandins. PDE-V inhibitors may also be 
used for treatment of digital ulcers, but their application is 
still “off-label”. Patients with systemic sclerosis and history 
of digital ulcers may be treated with bosentan for prevention 
of onset of new ulcers.
Future perspective
Diagnosis and treatment of Raynaud’s phenomenon is a 
major challenge in view of the wide variety of symptoms 
and pathophysiological mechanisms involved, especially in 
secondary Raynaud’s phenomenon due to connective tissue 
diseases. Pathological vascular conditions, but also structural 
abnormalities are suggested to play the major role in patho-
physiology of Raynaud’s phenomenon, but are still poorly 
understood. The key factors influencing these mechanisms 
are endothelin-1 and endothelial dysfunction, with consecu-
tive decreased nitric oxide synthesis being responsible for 
the imbalance of vasoconstriction and vasodilation. Hence, 
substances inhibiting vascular effects of endothelin-1 as 
well as improving endothelial function or enhancing nitric 
oxide-related effects as PDE-V inhibitors are suggested to be 
the most promising agents for future treatment and research, 
especially in secondary Raynaud’s phenomenon.Vascular Health and Risk Management 2010:6 213
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